MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

AbbVie Inc

Fechado

SetorSaúde

204.91 -0.44

Visão Geral

Variação de preço das ações

24h

Atual

Mín

200.38

Máximo

206.16

Indicadores-chave

By Trading Economics

Rendimento

-1.6B

-23M

Vendas

642M

15B

P/E

Médio do Setor

87.665

63.778

EPS

2.16

Rendimento de Dividendos

3.13

Margem de lucro

-0.152

Funcionários

55,000

EBITDA

-4.4B

535M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+4.51% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

3.13%

2.39%

Próximos Ganhos

25 de abr. de 2025

Próxima data de dividendos

15 de mai. de 2025

Próxima data de ex-dividendo

15 de abr. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

36B

371B

Abertura anterior

205.35

Fecho anterior

204.91

Sentimento de Notícias

By Acuity

33%

67%

106 / 386 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Neutral Evidence

AbbVie Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

27 de fev. de 2025, 22:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Mustang Bio to Exit Lease of Worcester, Mass. Manufacturing Facility

12 de fev. de 2025, 13:41 UTC

Grandes Movimentos do Mercado

Xilio Therapeutics Shares Surge Premarket on AbbVie Deal

31 de jan. de 2025, 13:28 UTC

Ganhos

AbbVie 4Q Revenue Tops Estimates as Skyrizi, Rinvoq Growth Surges

14 de mar. de 2025, 09:30 UTC

Principais Notícias

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

3 de mar. de 2025, 15:04 UTC

Aquisições, Fusões, Aquisições de Empresas

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. -- IBD

28 de fev. de 2025, 12:00 UTC

Principais Notícias

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

6 de fev. de 2025, 13:25 UTC

Principais Notícias
Ganhos

Bristol Myers Earnings Are a 'Tale of 2 Trends' as Guidance Falls Short. The Stock Is Falling -- Barrons.com

6 de fev. de 2025, 12:00 UTC

Ganhos

Bristol Myers Earnings Are 'a Tale of 2 Trends' as Guidance Falls Short -- Barrons.com

5 de fev. de 2025, 12:00 UTC

Principais Notícias

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

31 de jan. de 2025, 15:50 UTC

Principais Notícias
Ganhos

AbbVie Stock Jumps on Earnings and Revenue Beat -- Barrons.com

31 de jan. de 2025, 13:51 UTC

Ganhos

AbbVie Jumps After Its Powerhouses, Skyrizi And Rinvoq, Continued To Dominate -- IBD

31 de jan. de 2025, 13:47 UTC

Principais Notícias
Ganhos

AbbVie Stock Jumps on Earnings and Revenue Beat -- Barrons.com

31 de jan. de 2025, 13:24 UTC

Conversa de Mercado
Ganhos

AbbVie Gets More Upbeat on Skyrizi, Rinvoq -- Market Talk

31 de jan. de 2025, 12:46 UTC

Ganhos

AbbVie's Stock Pops 4% After Earnings Beat Estimates And Company Offers Upbeat View Of 2025 -- MarketWatch

31 de jan. de 2025, 12:39 UTC

Ganhos

AbbVie 4Q Global Rinvoq Net Revenue $1.83B, Up 46.2% >ABBV

31 de jan. de 2025, 12:38 UTC

Ganhos

AbbVie: Expect 2025 Revenue to Exceed Previous Peak >ABBV

31 de jan. de 2025, 12:38 UTC

Ganhos

AbbVie Now Sees Aesthetics Delivering High-Single-Digit Compound Annual Revenue Growth From 2025-2029 >ABBV

31 de jan. de 2025, 12:37 UTC

Ganhos

AbbVie Raises 2027 Combined Sales Outlook for Skyrizi, Rinvoq to More Than $31B >ABBV

31 de jan. de 2025, 12:37 UTC

Ganhos

AbbVie Reaffirms Expectations for High-Single-Digit Compound Annual Revenue Growth Rate Through 2029 >ABBV

31 de jan. de 2025, 12:36 UTC

Ganhos

AbbVie: 4Q Revenue Rose 6.1% on Operational Basis >ABBV

31 de jan. de 2025, 12:36 UTC

Ganhos

AbbVie 4Q Loss $22M >ABBV

31 de jan. de 2025, 12:36 UTC

Ganhos

AbbVie 4Q U.S. HUMIRA Rev $1.25B >ABBV

31 de jan. de 2025, 12:36 UTC

Ganhos

AbbVie 4Q Global Net Rev From Oncology Portfolio $1.69B >ABBV

31 de jan. de 2025, 12:36 UTC

Ganhos

AbbVie 4Q Global Skyrizi Rev $3.78B >ABBV

31 de jan. de 2025, 12:36 UTC

Ganhos

AbbVie 4Q International HUMIRA Rev $436M >ABBV

31 de jan. de 2025, 12:36 UTC

Ganhos

AbbVie 4Q Adj EPS $2.16 >ABBV

31 de jan. de 2025, 12:36 UTC

Ganhos

AbbVie Sees FY Adj EPS $12.12-Adj EPS $12.32 >ABBV

31 de jan. de 2025, 12:36 UTC

Ganhos

AbbVie 4Q Loss/Shr 2c >ABBV

31 de jan. de 2025, 12:36 UTC

Ganhos

AbbVie 4Q Global IMBRUVICA Rev $848M >ABBV

31 de jan. de 2025, 12:36 UTC

Ganhos

AbbVie 4Q Rev $15.1B >ABBV

Comparação entre Pares

Variação de preço

AbbVie Inc Previsão

Preço-alvo

By TipRanks

4.51% parte superior

Previsão para 12 meses

Média 215.57 USD  4.51%

Máximo 240 USD

Mínimo 190 USD

Com base em 16 analistas de Wall Street que oferecem metas de preço de 12 meses para AbbVie Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

16 ratings

12

Comprar

4

Manter

0

Vender

Pontuação Técnica

By Trading Central

201.34 / 210.78Suporte e Resistência

Curto Prazo

Neutral Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Weak Bullish Evidence

Sentimento

By Acuity

106 / 386 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.